: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Fiscal Year 2017 Financial Results Utica, New York

CONMED Corporation Announces

Fourth Quarter and Fiscal Year 2017 Financial Results

Utica, New York, January 31,

2018 --- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the fourth quarter and fiscal year ended December

Fourth Quarter 2017 Highlights

Fiscal Year 2017 Highlights

"We are very pleased with our fourth quarter results,

which included the continued acceleration of our top line, expanded gross margins, and improved earnings. The quarterly and full-year

results are the culmination of our strategic focus and the hard work of the entire CONMED team," commented Curt R. Hartman,

CONMED's President and Chief Executive Officer. "We believe that our continued investments in people and innovative

products position us well to drive further market penetration with an improved profitability profile going forward."

For the quarter ended December 31,

2017, domestic sales, which represented 50.9% of total revenue, increased 7.8%, driven by strong performances in both General Surgery

and Orthopedics. International sales, which represented 49.1% of total revenue, increased 10.4% compared to the fourth quarter

of 2016 on a reported basis. Foreign currency exchange rates, including the effects of the FX hedging program, had a positive impact

of $2.4 million on fourth quarter sales. In constant currency, international sales increased 8.0% versus the prior-year period.

For the fiscal year ended December

31, 2017, domestic sales, which represented 51.6% of total revenue, increased 3.0% as strong growth in General Surgery was offset

by a 2.1% decline in Orthopedics. International sales, which represented 48.4% of total revenue, increased 5.7% compared to 2016

on a reported basis. Foreign currency exchange rates, including the effects of the FX hedging program, had a positive impact of

$0.1 million on fiscal year 2017 sales. In constant currency, international sales increased 5.8% versus the prior-year period.

For the quarter ended December 31,

2017, reported net earnings totaled $46.7 million, compared to reported net earnings of $6.7 million a year ago. Reported diluted

net earnings per share were $1.65 in the quarter, compared to reported diluted net earnings per share of $0.24 in the prior-year

period. Reported net income for 2017 and 2016 includes restructuring costs, business acquisition costs, and legal costs. Additionally,

reported net income for the fourth quarter of 2017 includes a tax benefit of $1.13 resulting from the 2017 Tax Cuts and Jobs Act.

The effect of each of these items on reported net income and reported diluted net earnings per share appears in the reconciliation

of GAAP to non-GAAP measures below.

The Company excludes the costs of

special items including acquisitions, restructurings, legal matters, gains on the sale of assets, debt refinancings, amortization

of intangible assets, net of tax, as well as the impact of the 2017 Tax Cuts and Jobs Act from its adjusted diluted net earnings

per share. Excluding the impact of these items, adjusted net earnings(2) of $19.5 million increased 29.4% year over

year, and adjusted diluted net earnings per share(1) of $0.69 increased 27.8% year over year. The increase in adjusted

net earnings resulted primarily from the favorable impact of foreign exchange rates, higher sales, and improved gross margin.

For the fiscal year ended December

31, 2017, reported net earnings totaled $55.5 million, compared to reported net earnings of $14.7 million a year ago. Reported

diluted net earnings per share were $1.97, compared to $0.52 in the prior-year period. Additionally, reported net income for 2017

includes a tax benefit of $1.14 resulting from the 2017 Tax Cuts and Jobs Act. Excluding the impact of the special items as described

above and as provided in the reconciliation of GAAP to non-GAAP measures below, adjusted net earnings(2) of $53.3 million

increased 3.7% year over year and adjusted diluted net earnings per share(1) of $1.89 increased 2.7% from the prior

The Company expects full-year 2018

constant currency sales growth in the 4.0% to 5.0% range. Based on recent exchange rates, the positive impact to 2018 sales from

foreign exchange is anticipated to be between approximately 100 and 150 basis points.

In addition, the Company forecasts

full-year 2018 adjusted diluted net earnings per share in the range of $2.11 to $2.17. This represents growth over 2017 of approximately

12% to 15%. The adjusted diluted net earnings per share estimates for 2018 exclude the cost of special items including acquisition

costs and restructuring costs, which are estimated in the range of $3 to $5 million, net of tax, and amortization of intangible

assets, which are estimated in the range of $16 to $18 million, net of tax.

Supplemental Financial Disclosures

(1) A reconciliation

of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

(2) A reconciliation

of reported net income to adjusted net earnings, a non-GAAP financial measure, appears below.

The Company's management will

host a conference call today at 4:30 p.m. ET to discuss its fourth quarter and fiscal year 2017 results.

To participate in the conference

call, dial 844-889-7792 (domestic) or 661-378-9936 (international)

and refer to the passcode 2281848.

This conference call will also

be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com.

The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also

be available from 7:30 p.m. ET on Wednesday, January 31, 2018, until 7:30 p.m. ET on Wednesday, February 14, 2018. To hear this

recording, dial 855-859-2056 (domestic) or 404-537-3406 (international) and enter the passcode 2281848.

About CONMED Corporation

CONMED is a medical technology

company that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used

by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

CONMED has a direct selling presence in 17 countries, and international sales constitute approximately 50% of the Company's

total sales. Headquartered in Utica, New York, the Company employs approximately 3,100 people. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and today's

conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties,

which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements

herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause

actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risk

factors discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Any and all forward-looking

statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to

the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have

a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in

the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation

of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting

of its financial information determined under accounting principles generally accepted in the United States (GAAP) with certain

non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding

specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted income tax expense (benefit);

adjusted effective income tax rate; adjusted net earnings and adjusted diluted net earnings per share (EPS). The Company believes

that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial

results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and

the other adjusted measures described above are important indicators of its operations because they exclude items that may not

be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company's

underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring

aspects of the Company's cash flow. Management uses these non-GAAP financial measures for reviewing the operating results

and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation

on these non-GAAP financial measures.

To measure percentage sales growth

in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability

and trend of sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that